Flurbiprofen
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Flurbiprofen: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that is marketed in India in oral tablet and ophthalmic forms. The TxGNN model predicts it may be related to acromesomelic dysplasia, Hunter-Thompson type, but the prediction is supported by 0 clinical trials and 0 publications, so it remains a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Flurbiprofen belongs to the NSAID class, which acts mainly by inhibiting cyclooxygenase (COX) enzymes and reducing inflammation and pain.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare genetic skeletal dysplasia linked to the CDMP1/GDF5 pathway. No plausible mechanism is known by which COX inhibition would modify this disease. The high TxGNN score (0.9999) is a computational prediction based on network proximity to other skeletal phenotypes, not on clinical or laboratory findings.
At most, an NSAID might relieve secondary joint pain, which would be symptomatic relief rather than treatment of the underlying disorder. No data compiled for this report support even that use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 licences are recorded, all valid, and this list may be partial. The main ones are listed below; none of the records carries approved-indication text.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| 136158 | Migrid 10mg Tablet | Strip of 10 tablets (oral) |
| 139138 | Migrid 5mg Tablet | Strip of 10 tablets (oral) |
| 97660 | Gatidrops FP Eye Drop | Bottle of 5 ml eye drop |
| 164804 | Ocuflur Eye Ointment | Tube of 5 gm eye ointment |
| 84289 | Flur Ophthalmic Solution | Packet of 10 ml ophthalmic solution |
Safety Considerations
- Drug Interactions: 352 interactions are recorded. Examples rated Moderate include acetylsalicylic acid, hydrocortisone, dexamethasone, metformin, glimepiride, and mesalazine. Examples rated Minor include famotidine, cimetidine, and linaclotide.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications for this disease, and no plausible mechanism links COX inhibition to the underlying genetic defect.
To proceed, the following is needed:
- Any preclinical or clinical study directly addressing this disease
- Mechanism of action data and a credible biological rationale
- Package insert warnings and contraindications for the relevant formulations
- Assessment of whether the available oral and ophthalmic routes suit any proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.